Ikarovec was formed as a spin-out from the biotechnology company Quethera, which was acquired by Astellas Pharmaceuticals in 2018.
Dr Robert Haigh has more than 27 years experience in drug discovery, clinical development and commercialisation in the pharmaceutical and biotech industries. With over 20 years at Board level in the UK, Europe and USA, Robert brings to the company deep understanding of running a small biotech business, in-depth experience of drug development, a network of business advisers and investors supporting the biotech community and knowledge of the commercial landscape in ophthalmology.
In 2011 Robert was co-founder and COO of the NASDAQ-listed KalVista Pharmaceuticals, a transatlantic company with a therapeutic focus in ophthalmology and rare diseases. Robert was previously founder and CSO of Vantia Therapeutics after he led the spinout of small molecule assets from Ferring Pharmaceuticals where he was VP Research and CEO of the UK R&D site. Robert began his career in the pharma industry with Boehringer Ingelheim in Germany.
Robert is a recent past CEO of Neuro-Bio and currently serves as a non-executive director for Chain Biotechnology. Robert holds an MSc in Biochemistry and a PhD, both from the University of Manchester.
Peter S Widdowson
Founder, Director and Chief Technology Officer
Dr. Peter Widdowson has over 30 years of drug discovery experience during which he has worked on a number of small molecule, protein and gene therapy approaches to managing disease.
He has held a number of senior scientific roles within Servier (Research Group Leader), AstraZeneca (Senior Scientist and Project Research Manager), Pfizer (Senior Scientist and Project Research Manager), OSI Pharmaceuticals (Director of Pharmacology) and overseeing and managing the development of three lentiviral vector gene therapies for a number of indications whilst working at Oxford BioMedica.
Peter was the co-Founder and CEO of the gene therapy company, Quethera which was established in 2015 and sold to Astellas Pharma of Tokyo in 2018 to gain access to the novel retinal protection product for patients with glaucoma. Peter holds a Bachelor of Science degree in human Physiology from the University of Newcastle-on-Tyne (1981) and a PhD in neuropharmacology from Manchester University (1984).
Senior Leadership Team
Chief Scientific Officer
Dr Katie Binley has over two decades’ of gene therapy expertise. While at Oxford Biomedica she played a key role in the early stages of the bench-to-clinical transition of a range of gene therapy projects including several ocular indications (wet age-related macular degeneration, Stargardt Disease and Ushers Syndrome 1B).
She joined Oxford BioMedica in 1997 as one of the first scientists as the company was spun out of the Kingsman Laboratory in Oxford University, later becoming Director of Biology. In a recent project Katie managed a multi-disciplinary team to develop a novel Parkinson’s gene therapy that was licensed exclusively to a US -based company (Axovant Sciences) in 2018 in a multi-million dollar deal.
She joined Ikarovec from PepGen, a University of Oxford spin-out focused on addressing the delivery challenge of nucleic acid therapies, where she was Head of Preclinical Development.
Katie has a Dual Honours Degree in Genetics and Microbiology, and a PhD in Yeast Molecular Genetics, both from the University of Sheffield.
Investment Director UK Innovation & Science Seed Fund
Oliver invests from UKI2S, an early stage seed/series A fund that backs companies developing complex science and engineering led solutions to global challenges. Specialising in life science investments Oliver joined UKI2S in 2014. He has therapeutic, med tech, agritech and industrial biotech companies in the portfolio and sits on the board of Ikarovec, a gene therapy company and Gyreox, a macrocycle company as well as observer positions at the cell therapy company Cytox.
Prior to joining UKI2S Oliver managed commercialisation of bioengineering and medical technologies at Imperial Innovations and worked at Ark Therapeutics as well as managing a team of biotech buy-side analysts. Oliver has a BSc in Molecular Biology/Biotechnology and an MSc from Bristol University.
Mr. Morgan has served as the Chief Financial Officer at Verona Pharma since September 2016. From May 2014 to November 2015, Mr. Morgan was the Chief Executive Officer of C4X Discovery plc, a biotechnology company.
Prior to C4X, Piers co-founded uniQure N.V., a biotechnology company, in Amsterdam, where he served as Chief Financial Officer from December 2009 to May 2014. Piers received an M.A. in law and management studies from the University of Cambridge.
Dr Edward Bliss
General Counsel and Company Secretary of LifeArc
Dr Edward Bliss is General Counsel and Company Secretary of LifeArc and heads up LifeArc’s Legal division. In this role he is responsible for all governance, licensing, compliance, and in-house legal affairs.
Edward joined from Shire Pharmaceuticals plc, where he was Legal Director and lead counsel for Shire’s European Neuroscience business division, and provided legal support to its product wide Nordic and Russian businesses. Prior to Shire Edward was General Counsel and Company Secretary at Ark Therapeutics Group Plc, a research based, late development stage gene-therapy company listed on the London Stock exchange.
Dr Cassie Doherty
Investor Director from Parkwalk
Cassie Doherty is Investment Director with Parkwalk Advisors, the largest EIS growth fund manager focused on University spin outs. She has worked in life sciences investment for over 10 years and has experience in fundraising, licensing and acquisition, intellectual property and technology commercialisation.
Prior to this she led drug development programmes from academic research in Phase II clinical studies. She holds a PhD in Biochemistry and Molecular Biology.